MarketAnalysisMarketAnalysis
NYSE:BMY

Bristol-Myers Squibb Company - NYSE:BMY - Comprehensive analysis

Free evaluation through quantitative algorithms Bristol-Myers Squibb Company - NYSE:BMY

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

7.32

Market

66

Sector

60

Gross Profit Growth Over Prior Year

5.4

Market

47

Sector

55

EBITDA Growth Over Prior Year

5.36

Market

45

Sector

53

EBITA Growth Over Prior Year

5.5

Market

48

Sector

47

EBIT Growth Over Prior Year

13.65

Market

65

Sector

58

Earnings from Cont. Ops. Growth Over Prior Year

0

Market

0

Sector

0

Net Income Growth Over Prior Year

0

Market

0

Sector

0

Normalized Net Income Growth Over Prior Year

-3.54

Market

27

Sector

25

Diluted EPS before Extra Growth Over Prior Year

0

Market

0

Sector

0

A/R Growth Over Prior Year

-1.81

Market

30

Sector

23

Inventory Growth Over Prior Year

-3.94

Market

24

Sector

19

PPE Net Growth Over Prior Year

4.03

Market

58

Sector

70

Total Assets Growth Over Prior Year

-2.69

Market

22

Sector

43

Tangible Book Value Growth Over Prior Year

0

Market

0

Sector

0

Common Equity Growth Over Prior Year

-44.5

Market

3

Sector

12

Cash from Ops. Growth Over Prior Year

9.6

Market

62

Sector

52

CAPEX Growth Over Prior Year

3.23

Market

56

Sector

67

Dividend per Share Growth Over Prior Year

4.76

Market

53

Sector

96

Levered Free Cash Flow Growth Over Prior Year

22.7

Market

71

Sector

62

Unlevered Free Cash Flow Growth Over Prior Year

24.9

Market

73

Sector

66

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

76

Market

90

Sector

77

SG&A Margin %

16.28

Market

56

Sector

30

EBITDA Margin %

40.2

Market

80

Sector

97

EBITA Margin %

39

Market

92

Sector

98

EBIT Margin %

20.4

Market

57

Sector

90

Earnings from Cont. Ops Margin %

-18.49

Market

2

Sector

27

Net Income Margin %

-18.53

Market

2

Sector

28

Net Income Avail. for Common Margin %

-18.53

Market

2

Sector

28

Normalized Net Income Margin %

12.68

Market

65

Sector

91

Levered Free Cash Flow Margin %

35

Market

94

Sector

98

Unlevered Free Cash Flow Margin %

37.5

Market

93

Sector

98

Return on Assets %

6.55

Market

60

Sector

89

Return on Capital %

8.86

Market

56

Sector

90

Return on Equity %

-38.95

Market

1

Sector

45

Return on Common Equity %

-39.1

Market

1

Sector

46

Total Asset Turnover

0.51

Market

51

Sector

66

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 60
Momentum: 58
Growth: 47
Profitability: 50

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

2.89

Market

44

Sector

50

TEV/LTM EBITDA

7.06

Market

14

Sector

55

P/LTM Normalized EPS

16.65

Market

21

Sector

30

P/BV

6.3

Market

71

Sector

85

TEV/LTM Unlevered FCF

7.71

Market

4

Sector

49

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

-12.05

Market

17

Sector

53

3M Price Performance

-6.26

Market

51

Sector

75

6M Price Performance

0.13

Market

67

Sector

77

9M Price Performance

31.1

Market

92

Sector

90

1Y Price Performance

8.01

Market

62

Sector

82

Start analyzing Bristol-Myers Squibb Company - NYSE:BMY with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports